Genentech pays Alector $100M for preclinical Parkinson’s prospect
Genentech has entered a global license agreement with Alector for a preclinical brain-penetrant enzyme replacement therapy targeting Parkinson's disease.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Genentech and Roche entered into a global license agreement with Alector for a preclinical brain-penetrant GCase enzyme replacement therapy intended for Parkinson’s disease and other neurodegenerative diseases. Under the deal, Genentech paid Alector $100 million upfront, with potential total payments reaching up to $1.27 billion based on future goals.
Following the agreement, Alector's stock prices rose.
Epilogue added 39d ago, after coverage quieted.
The brief
Genentech has executed a global license agreement with Alector to develop a brain-penetrant GCase enzyme replacement therapy. This preclinical prospect is designed to treat Parkinson's disease as well as other neurodegenerative diseases. As part of the initial terms of the deal, Genentech is paying Alector $100 million. This collaboration focuses on delivering a therapeutic that can effectively penetrate the brain to address the underlying mechanisms of the targeted neurological conditions. Coverage of the deal highlights varying potential financial outcomes for Alector.
According to reporting from Stock Titan, the agreement could result in payments of up to $1.17 billion for Alector if specific future goals are met. Meanwhile, Reuters reports that Alector's stock soared following the news that Roche is licensing the Parkinson's therapy for a total potential value of up to $1.27 billion. FierceBiotech emphasizes the initial $100 million payment for the preclinical prospect, while finance.yahoo.com focuses on the global nature of the license agreement for the GCase enzyme replacement therapy. This transaction matters because it targets the difficult challenge of creating brain-penetrant therapies for neurodegenerative diseases. The focus on GCase enzyme replacement therapy represents a specific scientific approach to treating Parkinson's.
The involvement of major industry players like Genentech and Roche underscores the commercial interest in preclinical assets that can cross the blood-brain barrier. WBOC TV has categorized these developments under the broader umbrella of biotech breakthroughs and brain-related innovations. Future developments will depend on whether Alector can meet the future goals required to unlock the full value of the deal. Observers will be watching for updates on the preclinical progress of the GCase enzyme replacement therapy as it moves toward potential clinical trials. The financial trajectory of Alector will likely be tied to these milestones, as the difference between the initial payment and the maximum potential payouts reaches over a billion dollars based on the reports from Reuters and Stock Titan.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 41d ago.
Quick answers
How much is Genentech paying Alector initially?
Genentech is paying Alector $100 million for the preclinical Parkinson's prospect.
What is the maximum potential value of the deal?
Reports vary, with Stock Titan citing up to $1.17 billion and Reuters citing up to $1.27 billion if future goals are met.
What specific therapy is being licensed?
The agreement covers a brain-penetrant GCase enzyme replacement therapy for Parkinson's disease and other neurodegenerative diseases.
Coverage (7)
- Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset BioSpace · 41d ago
- Roche licenses Alector's brain-penetrant Parkinson's therapy for up to $1.3B FirstWord Pharma · 41d ago
- Biotech Brainiacs and Breakthroughs WBOC TV · 41d ago
- A Parkinson’s drug deal could mean up to $1.17 billion for Alector if future goals are met. Stock Titan · 41d ago
- Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases finance.yahoo.com · 41d ago
- Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion Reuters · 41d ago
- Genentech pays Alector $100M for preclinical Parkinson’s prospect fiercebiotech.com · 41d ago
Topics
Related trends
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.
Some people are resistant to dementia
Some people are resistant to dementia, sparking new research
Parkinson’s: beyond the brain
Recent coverage examines the expanding medical focus on the gut-brain connection regarding Parkinson's disease.
‘We both know how we feel about death and dying’: Rhys Ifans and Laura Linney on their brutally honest Parkinson’s drama
Rhys Ifans and Laura Linney lead 'Onwards and Sideways,' a brutally honest new drama centered on the realities of living with Parkinson's disease.
B-Vitamin Supplement Can Treat Psoriasis, a Skin Condition with No Cure
A cheap B‑vitamin pill shows promise in easing psoriasis symptoms, sparking hope for millions with the incurable skin disease
Anthropic's latest biotech buy is a one-man stealth startup run by a pseudonymous Twitter poster
Anthropic is expanding its biotech footprint by acquiring a stealth, one-person startup operated by a pseudonymous Twitter user.